Retatrutide 30 mg kit
Also known as · LY-3437943
Retatrutide 30 mg lyophilised vial kit — the mid-dose research presentation. Includes bacteriostatic water, syringes, and swabs.
Chemistry quick-facts
- CAS
- 2381089-83-2
- Formula
- C221H343N51O66
- MW
- 4729.4 Da
- Length
- 39 aa
- Status
- Investigational. Phase 3 trials under the TRIUMPH programme. Not approved anywhere.
- Purity (HPLC)
- ≥ 99.2%
Mechanism of action
Simultaneous agonism at GLP-1, GIP, and glucagon receptors. The added glucagon-receptor agonism is proposed to drive energy-expenditure effects in addition to incretin-mediated insulin secretion.
Research context
Retatrutide (LY-3437943) is an investigational triple-agonist peptide being studied in Phase 3 trials. The 30 mg vial is the mid-dose presentation, widely used in extended research protocols and analytical-chemistry reference work.
Every lot is tested by Janoshik Analytical in Slovakia: HPLC for purity, ESI-MS for identity. COA is published on the product page before the lot lists for sale.
Published studies
A non-exhaustive list of peer-reviewed studies referenced when curating this entry. Click through to the primary source for the full text.
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM.
- Rosenstock J, et al. (2023). Retatrutide in people with type 2 diabetes — Phase 2. The Lancet.
Active clinical trials
- NCT05929066Phase 3 · Ongoing
TRIUMPH-1: Retatrutide in obesity
Reconstitution
- Solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- · Inject diluent slowly down the side of the vial onto the cake.
- · Swirl gently — do not shake.
- · Solution should be clear and colourless. Discard if not.
Storage
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life — sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
FAQ
How does this differ from the 40 mg pen?+
Same active peptide. The vial kit is lyophilised and requires reconstitution (bac water and syringes included); the pen is pre-filled and shipped cold-chain. Vial kits have a longer shelf life and do not require cold-chain shipping.
This page summarises the research literature on Retatrutide 30 mg kit for in vitro laboratory investigation only. It is not medical advice, not a treatment recommendation, and not a substitute for a qualified physician. Material is sold for analytical chemistry and cell-culture research, not for human or veterinary administration.
- ResearchRetatrutide 40 mg pen
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue
- ResearchRetatrutide 10 mg kit
Retatrutide 10 mg lyophilised vial kit — entry-point research presentation. Includes bac water, syringes, swabs.
- BiomarkerHOMA-IR 2.5
HOMA-IR is a calculated index from fasting glucose × fasting insulin. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance, often years before HbA1c shifts.
- BiomarkerFasting insulin 12
Fasting insulin of 12 µIU/mL is above the optimal threshold most metabolic research uses (~8). What it indicates, why doctors miss it, and the research literature on early insulin resistance.
- BiomarkerHbA1c 5.7%
HbA1c at 5.7% is the formal threshold the ADA uses to define prediabetes — meaning your average blood glucose has been elevated over the past 2–3 months. What the number means and the research literature on intervention.
- ResearchCagrilintide 10 mg
Cagrilintide is a long-acting amylin analogue most widely investigated in combination with semaglutide under the CagriSema programme. Commonly stacked